Pages that link to "Q36298443"
Jump to navigation
Jump to search
The following pages link to Statistical evaluation of biomarkers as surrogate endpoints: a literature review (Q36298443):
Displaying 50 items.
- The perils of surrogate endpoints (Q27025740) (← links)
- Comparing Biomarkers as Principal Surrogate Endpoints (Q28740935) (← links)
- Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy (Q30833179) (← links)
- Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists (Q33600372) (← links)
- Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal (Q33621249) (← links)
- Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis (Q33769712) (← links)
- Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene (Q33933021) (← links)
- Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients (Q34247688) (← links)
- Choosing inclusion criteria that minimize the time and cost of clinical trials (Q34367570) (← links)
- Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer (Q34866341) (← links)
- A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables (Q35016789) (← links)
- Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time (Q35556037) (← links)
- A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials (Q35681400) (← links)
- A bayesian approach to surrogacy assessment using principal stratification in clinical trials (Q36002474) (← links)
- Biomarkers and surrogate endpoints in kidney disease (Q36284659) (← links)
- Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology (Q36349459) (← links)
- Clinical applications of whole-genome association studies: future applications at the bedside (Q36528872) (← links)
- Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making (Q36557345) (← links)
- Surrogate endpoint analysis: an exercise in extrapolation (Q36727471) (← links)
- The risky reliance on small surrogate endpoint studies when planning a large prevention trial (Q36740585) (← links)
- A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials (Q36740970) (← links)
- Primer: measuring the effects of treatment in clinical trials (Q36807481) (← links)
- Requirements for benefit assessment in Germany and England - overview and comparison (Q36944500) (← links)
- The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat (Q36966415) (← links)
- ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. (Q37012786) (← links)
- Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus (Q37101364) (← links)
- The role of clinical imaging in oncological drug development (Q37187098) (← links)
- Tracking biocultural pathways in population health: the value of biomarkers (Q37385281) (← links)
- Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer (Q37389608) (← links)
- The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES). (Q37418999) (← links)
- Biomarkers in oncology drug development (Q37453841) (← links)
- Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. (Q37458317) (← links)
- Mediation and moderation of treatment effects in randomised controlled trials of complex interventions (Q37553613) (← links)
- Biomarkers and surrogate end points--the challenge of statistical validation (Q37724573) (← links)
- Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study (Q37780882) (← links)
- Integrating biomarkers in clinical trials (Q37853183) (← links)
- Considerations for Endpoint Selection When Designing HIV Clinical Trials (Q37967498) (← links)
- A statistician's perspective on biomarkers in drug development. (Q37967642) (← links)
- Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. (Q38259501) (← links)
- Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? (Q38389980) (← links)
- Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review. (Q38590481) (← links)
- An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest (Q38763752) (← links)
- Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial. (Q38796580) (← links)
- A Bayesian hierarchical surrogate outcome model for multiple sclerosis (Q38803203) (← links)
- Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy (Q38852314) (← links)
- Developing retinal biomarkers of neurological disease: an analytical perspective (Q39199351) (← links)
- Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide (Q39572955) (← links)
- Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach (Q39723955) (← links)
- Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials (Q39906181) (← links)
- Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches (Q40369130) (← links)